From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia
Authors:
- Andrea AstolfiAAAndrea Astolfi
- Francesca MilanoFMFrancesca Milano
- Deborah PalazzottiDPDeborah Palazzotti
- Jose BreaJBJose Brea
- Maria Chiara PismataroMPMaria Chiara Pismataro
- Mariangela MorlandoMMMariangela Morlando
- Oriana TabarriniOriana Tabarrini
- Maria Isabel LozaMLMaria Isabel Loza
- Serena MassariSerena Massari
- Maria Paola MartelliMMMaria Paola Martelli
- Maria Letizia BarrecaMBMaria Letizia Barreca
Open Access
- 26 October 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2295
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy whose prognosis is globally poor. In more than 60% of AML patients, the PI3K/AKTs/mTOR signaling pathway is aberrantly activated because of oncogenic driver alterations and further enhanced by chemotherapy as a mechanism of drug resistance. Against this backdrop, very recently we have started a multidisciplinary research project focused on AKT1 as a pharmacological target to identify novel anti-AML agents. Indeed, the serendipitous finding of the in-house compound T187 as an AKT1 inhibitor has paved the way to the rational identification of new active small molecules, among which T126 has emerged as the most interesting compound with IC50 = 1.99 ± 0.11 μM, ligand efficiency of 0.35, and a clear effect at low micromolar concentrations on growth inhibition and induction of apoptosis in AML cells. The collected results together with preliminary SAR data strongly indicate that the 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one derivative T126 is worthy of future biological experiments and medicinal chemistry efforts aimed at developing a novel chemical class of AKT1 inhibitors as anti-AML agents.Keywords
Funding Information
- European Research Council (725725)
This publication has 52 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathwayLeukemia, 2011
- The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemiaLeukemia, 2009
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaBlood, 2006
- Perturbations of the AKT signaling pathway in human cancerOncogene, 2005
- Inhibition of tumor cell proliferation by thieno[2,3-d]pyrimidin-4(1H)-one-based analogsBioorganic & Medicinal Chemistry Letters, 2005
- PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathwaysLeukemia, 2005
- Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometryBritish Journal of Haematology, 2004
- The Protein Data BankActa Crystallographica Section D Structural Biology, 2002
- PKB/AKT: functional insights from genetic modelsNature Reviews Molecular Cell Biology, 2001